Mabwell has established a licensing and commercialisation agreement with a strategic business partner in Malaysia for its Denosumab biosimilar products MAILISHU (a biosimilar of Prolia) and MAIWEIJIAN (a biosimilar of Xgeva). Under the agreement, the partner is responsible for the registration and commercialisation of the products in Malaysia, while Mabwell is responsible for the development, production and commercial supply for the products.

Malaysia has a population of approximately 35.97 million, with a Gross Domestic Product (GDP) at a leading level in Southeast Asia. As a full member of PIC/S, the country boasts the most mature and well-regulated pharmaceutical regulatory framework in the ASEAN region.

In terms of the pharmaceutical market, Malaysia's market size stood at approximately USD 3.4 billion in 2025, maintaining a Compound Annual Growth Rate (CAGR) of about six percent, indicating big market potential.